Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Arrowhead Pharmaceuticals ( (ARWR) ) has provided an announcement.
On September 10, 2025, Arrowhead Pharmaceuticals filed a lawsuit against Ionis Pharmaceuticals in the United States District Court for the District of Delaware. The lawsuit seeks a declaratory judgment that Ionis’s U.S. Patent No. 9,593,333 is invalid and/or not infringed by Arrowhead’s planned commercialization of investigational plozasiran. This legal action could impact Arrowhead’s operations and its position in the RNAi therapeutics market, particularly concerning its advanced drug candidate, plozasiran, which has shown promise in treating familial chylomicronemia syndrome (FCS) by significantly reducing triglycerides and pancreatitis risk in patients.
The most recent analyst rating on (ARWR) stock is a Buy with a $42.00 price target. To see the full list of analyst forecasts on Arrowhead Pharmaceuticals stock, see the ARWR Stock Forecast page.
Spark’s Take on ARWR Stock
According to Spark, TipRanks’ AI Analyst, ARWR is a Neutral.
Arrowhead Pharmaceuticals’ overall stock score is primarily impacted by its challenging financial performance, which is a significant risk factor. However, strong technical indicators and positive corporate events, such as the Novartis partnership, provide some optimism. The valuation remains a concern due to negative earnings, but the earnings call suggests potential for future growth through strategic initiatives.
To see Spark’s full report on ARWR stock, click here.
More about Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biopharmaceutical company specializing in RNA interference (RNAi) technology to create therapeutics for various diseases, including orphan diseases with limited treatment options. Their therapies focus on targeting the underlying disease using their TRiM™ (Targeted RNAi Molecule) platform.
Average Trading Volume: 2,266,433
Technical Sentiment Signal: Buy
Current Market Cap: $3.99B
For an in-depth examination of ARWR stock, go to TipRanks’ Overview page.